Metraipolis › archive › dc_b528ebea2dc2

Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome — Europe PMC PMID:41566667

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41566667
DOI
10.1002/advs.202511449
License (as archived)
solo-consultazione
Archived
2026-11-06T15:13:19.784Z
SHA-256 of the archived text
6805ea106c730d9edcc6f6366402f8958a5c4db70e22e1948df9e8a7a38a101f
Stable URL of this page
https://metraipolis.com/documento/dc_b528ebea2dc2

How to cite

Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome — Europe PMC PMID:41566667 — Europe PMC (en), https://europepmc.org/article/MED/41566667 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b528ebea2dc2 (Metraipolis archive dc_b528ebea2dc2, sha256 6805ea106c730d9edcc6f6366402f8958a5c4db70e22e1948df9e8a7a38a101f)
BibTeX
@misc{dcb528ebea2dc2,
  title = {Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome — Europe PMC PMID:41566667},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41566667},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b528ebea2dc2; sha256 6805ea106c730d9edcc6f6366402f8958a5c4db70e22e1948df9e8a7a38a101f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41566667. Agents can read the archived copy with the MCP tool read_document.